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Summary. In Parkin on ' di ea e the dopaminergic inhibition - mediated by 
DA2 receptors in the triatum - i reduced. Therefore glutamatergic excitation 
predominates in the antero-dorsal striatum. In turn the glutamatergic neuron 
of the subthalamic nucleu become di inhibited. Antagoni t of the NMDA-
ubtype of glutamate receptor injected locally into the glutamatergically 
innervated nuclei or competitive and non-competitive NMDA-antagoni t 
administered systemically, counteract parkinsonian ymptom in animals. 
Introduction"" 
It has taken a long time from the first demonstration of the excitatory actions of 
GLU in 1958, to it general acceptance a a centrally acting neurotransmitter 
(for review see Watkins, 1988). Today, GLU is considered to be the main 
transmitter mediating synaptic excitation in the mammalian brain. GLU is the 
transmitter of several ubcortical projection ,of ome cortical afferents and of 
intracortical connections. Mo t probably all corticofugal projection use GLU 
as their transmitter. Thus, al 0 the basal ganglia receive ma ive glutamatergic 
afferents from the cerebral cortex (Fonnum, 1984). 
Functional anatomy of the basal ganglia 
There is growing evidence for the existence of loop from the cortex via the 
striatum, the pallidum and the thalamus back to the cortex (Alexander, 1986). 
These loops are con idered in the present context as " main loop " . Two .. ide 
loops" exist that may influence information proces ing through the main 
loops: First, a loop from the striatum to the SNc, back to the striatum using 
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GABA and DA as transmitters and second, a loop from the GPe to the STN 
back to the GPilSNr using GABA and GLU as transmitters (Fig. 1). 
The striatum is the main input station of the basal ganglia. Previously, the 
striatum has been considered as a funnel receiving converging and overlapping 
projections from the cortex. Nowadays it is thought that the somatosensory 
cortices preferentially innervate the putamen while the association cortices 
innervate the nucleus caudatus. These cortical inputs are arranged in such a 
way that a specific cortical area projects upon a specific (associated) area of 
the putamen or nucleus caudatus respectively. In both striatal structures the 
inputs remain segregated and, from preliminary evidence, it has been sug-
gested that thi s segregation may be preserved through the whole main loops. 
The striatum and its ventral extension, the nucleus accumbens, receive 
glutamatergic afferents al 0 from the hippocampus and amygdala (Walaas, 
1981). 
Most important for our view about segregated information processing 
through the main loops and possible integration is the finding of Haber et al. 
( 1985) who showed the existence of a direct projection from the GPe to the 
reticular nucleus of the thalamus which projects to other thalamic nuclei but 
not to the cortex. These various connections may represent the substrate by 
which basal ganglia outputs inhibit or disinhibit thalamic activity and that of 
thalamocortical afferent neurons, which are thought to be GLUergic . 
The striatal output neurons (medium sized spiny I neurons) are GABA-
ergic : They project to the GPe and to the SNr/GPi in the course of the main 
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Fig. 1. Schematic di agram of the circuitry and neurotransmitters of the basa l gang lia. GPe 
globus pallidu ex ternal segment ; GPi globus pallidus internal segment; SNr substanti a 
nigra pars reticulata: SNc substanti a nigra pars compacta; STN subthalamic nucleus; THAL 
thalamus: DA dopamine; GABA gamma-aminobutyri c acid; GLU L-glutamic acid 
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loops and in a side loop to the SNc. The excitatory GLUergic input from the 
cortex activates the inhibitory triatofugal GABAergic neuron . Via a direct 
pathway through the GPi/SNr, such a cortical input to the triatum activates the 
thalamic relay nuclei. But via an indirect pathway through GPe, STN , GPi/SNr 
a cortical input inhibits the thalamic relay nuclei (Fig. I). 
Within the striatum, the DAergic neurons of the side loop ascending from 
the SNc are both inhibitory and excitatory: DA activate through D I-receptors 
those GABAergic output neurons that use ub tance Pas cotransmitter and that 
project directly to the SNc or to the GPi/SNr. But DA inhibits through D2-
receptors the GABAergic neurons of the indirect pathway that use enkephalins 
as cotransmitters and project to the GPe (Gerfen et aI., 1990). Thus, in contrast 
to a GLUergic input, DA relea e within the triatum re ults in a uniform effect 
on thalamic relay nuclei: DA - via D2-receptors - inhibits the striatofugal 
output neurons of the indirect pathway but excites - via D I-receptors - striatal 
output neurons of the direct pathway. Therefore, in the striatum exists a 
balance between GLU that activates, and DA that inhibits the GABAergic 
neurons of the indirect pathway. 
Glutamate receptors in the basal ganglia 
GLU binds to at least three different receptor types: Two are ionotropic and 
labelled according to their preferred agonists, i.e. the NMDA - and the AMPA 
receptor and one is a metabotropic G-protein coupled receptor. 
Among the basal ganglia nuclei , the striatum has the highest density of all 
glutamate receptors (Albin et aI., 1992). The density of NMDA receptors in the 
striatum of rats (Monaghan and Cotman, 1985; Albin et aI., 1992) and in the 
nucleus caudatus and putamen of monkeys (Young et aI. , 1990) is approxi-
mately one half of the den ity of NMDA receptors found in the hippocampus 
where the highest densities occur (Young et aI., 1990) and about ten fold higher 
than in the other nuclei of the basal ganglia. 
AMPA and metabotropic receptor densities as shown by quisqualate bind-
ing, are approximately 30% lower in the striatum than in the hippocampus 
(Young et aI., 1990). AMPA receptor density in the striatum is approximatly 4 
fold higher while the density of the metabotropic receptor is only about 2 fold 
higher than in other basal ganglia nuclei (Albin et aI., 1992). 
Behavioural pharmacology 
Dysfunctions of the transmitter balance within all basal ganglia loops cause 
motor and cognitive deficiencies in animals and men. In the following , the 
dependence of several behavioural variables from the DA- GLU balance in the 
basal ganglia will be considered. 
68 W. J . Schmidt et al. 
Catalepsy 
Catalepsy in the rat is a tate of postural immobility (akinesia), muscular 
rigidity (rigor) and tremor of the limbs due to an experimentally induced 
OAergic deficiency (Sanberg et aI., 1988; Colpaert, 1987). Catalepsy i a 
condition in which those systems of the brain, involved in the initiation of 
voluntary movements are inoperative but in which the animal is awake and 
tho e ystem of the brain involved in reflexive control, static postural support 
and equilibrium are operative (Schallert and Teitelbaum, 1981). Although the 
internally generated (arbitrary) initiation of behaviour is inoperative, strong 
ex ternal stimuli such as tail pinch, cold water (Ungerstedt, 1974) or key stimuli 
adequate to activate innate releasing mechanjsms (Schmjdt, 1984; Wegener et 
aI., 1988) can activate an otherwi e cataleptic anima1. 
Catalepsy is induced by all treatments that reduce the activity of the 
meso triatal and mesolimbic OAergic neurons, for example by reserpine 
(Colpaert, 1987), <x-MPT or by blockade of postsynaptic OA receptors by 01-
or 02-receptor-antagonists (bgren and Fuxe, 1988; for review see Schultz, 
1982). As hown by Sanberg ( 1980), postsynaptic, not presynaptic OA 
receptors mediate neuroleptic-induced catalepsy. Local destruction of OA cells 
in the SNc with 6-0HOA or MPP+ or the destruction of the a cending OA 
neuron to the striatum al 0 induce catalepsy. However, lesions of the 
dopaminergic terminal within the prefrontal cortex do not induce catalepsy 
but rather have stimulating effect on behaviour, i.e. induction of locomotion 
(Bubser and Schmidt, 1990). 
Recently adenosine A2 agonists have been reported to induce catalepsy in 
the rat. Thi wa explained by the existence of a central A2ID2 receptor 
interaction , i.e. by the A2-induced inhibition of 02 transmission (Fern! et aI., 
1991). GLU excites and OA inhibits the striatal output neurons of the indirect 
pathway via the GPe. Given that OA and GLU via the NMOA receptor have 
oppo ite behavioural effects in the striatum (Schmidt, 1986a; Girault et aI., 
1990) admini tration of NMOA would be expected to induce catalepsy. In fact , 
NMOA given systemically (7.5 , 15, 30mg/kg i.p. ) or locally into the striatum 
(0.5 and I ~) (Schmidt and Bury, 1988) reduced all behavioural activities, but 
it did not induce catalep y. However, when NMOA (40mg/kg i.p. ) was given 
in combination with haloperidol , it potentiated the cataleptogenic effects of 
haloperidol (Mehta and Ticku , 1990). 
Reversal of catalepsy 
Systemic admini tration of drugs 
A treatment is considered to be anti cataleptic if I) it reduces the time span from 
placement of the animal into an unusual posture until the first active movement 
to correct thi posture and 11) if it doe not di sturb reflexive control, static 
postura l upport and equilibrium. 
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Catalep y due to DA-deficiency i rever ed by indirect and direct DA-
agonists: L-DOPA, amphetamine and other treatment that enhance pre ynaptic 
OA re lease are effec tive and po tsynaptic 0 2-agoni t uch a bromocriptine a 
well. An anticataleptic effect of a 0 I-agonist has not unequi vocally been hown 
as yet (for review see Sanberg et al. , 1988; Wachtel, 1991 ). 
Anticholinergic drug antagoni ze catalep y as well (Hillegaart and 
Ahlenius 1987). 
Because of the oppo ite effects of DA and GLU on akine ia and rigidity 
(Schmidt, 1986a), antagonists of glutamatergic transmission hould be able to 
compensate for the behav ioural effect of reduced OA acti vity and thu may 
have anticataleptic effects. In fac t, thi has been hown at first for di zoc ilpine 
(MK-801 ), a sub tance that blocks the NMOA recepto r gated ion channel 
when in its open state. Do e-dependendl y (0 .08, 0. 16, 0 .33 mg/kg i.p. ) 
di zocilpine reversed haloperidol (0.5 mg/kg i.p.) - induced catalepsy (Schmidt 
and Bubser, 1989; Elliott et a I. , 1990). Mehta and Ticku ( 1990) confirmed thi 
findin g and additionally showed a potenti ati on of the anticataleptic effect of 
scopolamine and bromocriptine by dizocilpine. Dizocilpine al 0 reversed 
catalepsy induced by the 0 I-antagonist SCH 23390 (Schmidt et aI. , 199 1). The 
aminoadam antane memantine. used clinicall y in the treatment of pastic ityand 
Parkinson 's di sease, has been shown to behave as a non-competiti ve NMDA-
antagonist (Bormann, 1989; Kornhuber et aI. , 1989). Memantine antagoni zed 
cata lepsy induced by neuroleptics or by DA-depletion with reserpine and u-
MPT (Maj et aI. , 1974; Schmidt et aI. , 1991 ). 
The blockade of the NMDA binding-site by the competiti ve NMDA-
antagoni sts CGP 37849, CGP 39551 and SDZ EAA 494 (Lowe et aI. , 1990) 
had anti cataleptic effects as well (Kretschmer et al. . 1992). AI 0 a ll osteric 
modul ation of the NMDA receptor via its glyc ine binding- ite influences 
catalepsy: the glycine-antagoni st 7-chlorokynureni c ac id (given i.c.v.) antago-
ni zed haloperidol-induced catalepsy (Kretschmer and Schmidt, 1992). The 
g lycine-agonist D-cyclo erine (i.p.) did not affec t catalepsy when given alone 
but it aboli shed the anticata lepti c effect of the competiti ve NMDA-antago-
ni sts. The anti cataleptic potency of di zocilpine was enhanced (Kretschmer et 
a l. , 1992). This latter finding may be ex plained by an increase in the opening 
rate of NMDA receptor gated ion channels where dizoc ilpine binds use-
dependent ly (Wong et al.. 1987). 
There is less evidence about the in volvement of non-N MDA receptors. The 
AMPA antagoni sts NBQX and GYKl 52466 did not change haloperidol-
induced catalepsy (Zadow and Schmidt. I 992a). 
Local admini strati on of dru gs 
Striatum : Yoshida et al. ( 1991 ) in ves ti ga ted the in volvement of the corti co-
tri ata l glutamate rgic projection in the inducti on of halo peridol-induced cata-
lepsy. To thi s end they ablated the frontal cortex and injected various 
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glutamatergic drugs into the striatum. In accordance with previous studies 
done by Scatton et al. (1982) and Worms et a1. (1985) it was shown that 
bilateral lesions of the frontal cortex markedly reduced the cataleptic effect of 
haloperidol. Further it was found that the selective blockade of NMDA 
receptors with AP-5 within the rostral striatum reduced catalepsy analogous to 
that produced by interruption of the cortical efferents. A non NMDA-antago-
ni st was ineffective in thi s respect. NMDA locally injected into the striatum 
was able to restore haloperidol -induced catalepsy in frontally decorticated rats 
(Yoshida et aI., 1991). 
The critical involvement of striatal NMDA receptors is further emphasized 
by lesion studies with the neurotoxin quinolinic acid. Quinolinic acid acts 
preferentially via NMDA receptors and destroys spiny I neurons; striatal 
interneurons en passage are spared. Such lesions in the striatum also prevent 
the induction of catalepsy (Schmidt and Bischoff, 1988; Calderon et aI., 1988). 
Quinolinic acid lesions of the lateral striatum most effectively prevent cata-
lepsy while lesions of the medial striatum rather affect cognitive processes 
(Hauber, 1990a). This latter finding nicely corroborates the view of segregated 
loops mediating different aspect of behaviour. 
Other basaL gangLia nuclei: Taken together, the results reported so far strongly 
support the view that the striatum (lateral part) is an essential constituent of a 
loop mediating catalepsy (Hauber, 1990a). Because only in the indirect path-
way DA and GLU (via the NMDA receptor) have opposite roles, thi s pathway 
(from the striatum to the GPe, STN, THAL) may represent the neuro-
anatomical substrate of this loop. Direct evidence for the involvement of this 
pathway in akinesia and rigidity derives from experiments with MPTP-treated 
monkeys: The MPTP-induced 10 s of triatal DA leads to overactivity of the 
striato-GPe neurons as shown by binding studies (Robertson et aI., I 990a), by 
in si tu hybridi sation (Augood et aI., 1989) and microdialysis experiments 
(Robertson et aI. , 1990b). Such overactivity inhibits the GPe and di sinhibits 
the STN in the side loop (DeLong, 1990; Aziz et aI., 1991 ) which in turn 
acitvates the GPi/SNr (Fig. I ). Lesions of the STN or AMPA receptor blockade 
with NBQX in monkeys antagonized MPTP-induced akinesia and rigidity 
(Aziz et aI. , 1991 ; Greenamyre et aI., 1991 ). The NMDA-antagonist CPP 
reduced rigidity also in monoamine-depleted rats when locally injected into 
the STN or GPi/SNr (Klockgether and Turski, 1990). Quinolinic acid lesions 
of the entopeduncular nucleus of the rat, the homologue of the GPi , which is 
overactive in DA-deficiency states, did not change catalepsy. However 
reserpine and haloperidol-induced catalepsy was reduced, if additionally 
AMPA receptors were blocked by systemically administered GYKl 52466 
(Zadow and Schmidt, 1992 b). 
GLUergic transmission is also operative in the other ide loop through the 
SNc: The SNc receives a cortical GLUergic input (Fig. I) (Carter, 1982; 
Kornhuber, 1984; Otter en and Storm-Mathisen, 1986). Electrical stimulation 
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of the cortex (N ieoullon et aI., 1978) and iontophoretically admini tered GLU 
enhance the relea e of DA in the SNc which may inhibit nigro triatal DAergic 
neuron by autoreceptors (Araneda and Bu to , 1989). Blockade of NMDA 
receptors in the SNc with locally admini tered AP-5 (5 nmoVO.5~) reduced 
haloperidol-induced catalep y (Schuster and Schmidt, 1988 ' Schu ter, 1990). 
Locomotion and stereotypy 
The locomotor acti vity of an animal is influenced by variou moti ational 
states and environmental variable. Drug belonging to diver e cia e with 
different mechani sm of action change locomotor activ ity. However there i 
unequivocal evidence that DA in the basal ganglia is critically involved in 
locomotor control: Drugs that facilitate OAergic transmission induce a syn-
drome characterized by increased locomotion and tereotyped behaviour 
(Randrup and Munkvad, 1967). Stereotypy can be defined as the performance 
of an invariant sequence of movement in a repetitive manner (Fray et al.. 
1980) not controlled by external st imuli. Stereotypy i pecie - pecific . In the 
rat it is manifested a continuous running, rearing and niffing at low to 
medium dose of DA-agonist , as continuou sniffing in one location , gnaw-
ing, biting, licking at high doses. At extremely high do es the animal cease to 
move although it i highly alert (for review see Lyon and Robbin , 1975). 
OAergic antagonist reduce spontaneou locomotor activity of rats and 
antagonize OA-agonist-induced hyperlocomotion and stereotypy. Thi antago-
nism i one of the most widely u ed screening procedure for neuroleptic drug. 
Classical neuroleptics, such as haloperidol antagonize stereotypy and locomo-
tion while the atypical ones, for example clozapine, do not antagonize tereotypy 
but specifically locomotion (Ljungberg and Unger tedt, 1978. 1985: Robert on 
and MacDonald, 1984). Thus antagonism of OA-induced locomotion is thought 
to correlate with the antip ychotic potency of neuroleptic drug. 
A with catalep y, OA and GLU appear to have opposite effects also 
on locomotion and stereotypy : The non-competitive NMOA-antagonist 
dizocilpine strongly stimulated locomotion and behaved like amphetamine in 
the rotational model (Clineschmidt et aI., 1982), additionally niffin g was 
enhanced (Tiedtke et aI., 1990). However, in contra t to OA-agoni sts the 
focused tereotypies e.g. sniffing in one location and the oral stereotypi e e.g. 
gnawing, biting, licking did not occur under dizocilpine. euroleptic drugs 
antagonized dizocilpine-induced hyperlocomotion , rotational behaviour and 
niffing (Clineschmidt et aI., 1982). Interestingly, al 0 the atypical neuroleptic 
clozapine antagonized the dizocilpine effects (Tiedtke et aI., 1990). 
The competitive NMOA-antagonists did not induce uch a pronounced 
stimulation of locomotion and stereotypy, in fact , low and medium do e of 
SOZ EAA 494 (Svensson et aI., 1991) CGP 37849 and CGP 39551 did not 
enhance locomotion of rats 45 min after drug administration; niffing wa. 
slightly enhanced (Kretschmer et aI., 1992). However when SOZ EAA 494 
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was given at higher do es (10, 20, 40 mglkg) to mice and the observation 
period wa extended, then between 60 and 160 min after drug administration 
locomotor stimulation was observed (Sven son et aI. , 1991). 
Reversal of DA-deficiency-induced locomotion -
and sniffing deficit 
Systemic administration of drugs 
It is well known that DA-agoni ts restore locomotor activity in DA-deficient 
animals and parkin onian patients (for review see Wachtel , 1991) confirming 
the view that DA plays the most crucial role in the induction of locomotion. 
Thus, it wa a most important finding that in monoamine depleted mice, i.e. in 
the complete absence of DA, the non-competitive NMDA-antagonist 
dizocilpine produced marked locomotor timulation (Carlsson and Carlsson, 
1989, 1990, but see also Goodwin et aI., 1992) as did the competitive NMDA-
antagonist SDZ EAA 494 (Kannari and Markstein, 1991). Also in monoamine 
depleted rat (Schmidt et aI. , 1990b) or in rats pretreated with haloperidol, 
dizocilpine stimulated locomotion but CGP 37849 (2 and 4 mg/kg, 45 min 
before test) was ineffective in this respect (Kretschmer et aI. , 1992). Addition-
ally when coinjected with L-DOPA, competitive (CPP) and non-competitive 
(dizocilpine) NMDA-antagonists have been shown to potentiate the ability of 
L-DOPA to restore locomotion in monoamine depleted rats (Klockgether and 
Turski , 1990). Goodwin et al. (1992) reported that dizocilpine potentiates D 1-
but not D2-dependent locomotion. 
Taken together, from these findings it appears that GLU potently depresses 
locomotion while blockade of NMDA receptors seems to be a general princi-
ple by which locomotion i enhanced. The non-competitive NMDA-antago-
nist were found to be more potent in this respect than the competitive ones 
(Schmidt et aI. , 1991). The AMPA-antagonist NBQX stimulated locomotor 
activity in re erpine-treated rat and MPTP-treated monkeys when given alone 
(Klockgether et aI. , 1991) or when coadministered with a threshold dose of L-
DOPA (Loschmann et aI. , 1991). 
Sniffing reduced by DA-deficiency, was restored by DA-agonists (Kelly et 
aI. , 1975) a well as by NMDA-antagoni ts (Tiedtke et aI. , 1990). As with loco-
motion, the ·non-competitive NMDA-antagonists were much more potent than 
the competitive antagonists . DCS, an agonist at the glycine binding site of the 
NMDA receptor was without any effect when given alone, when coadministered 
it potentiated dizocilpine-induced sniffing (Kretschmer et aI. , 1992). 
Local administration of drugs 
Striatum: DA in the nucleus accumbens, i.e. the ventral striatum, is involved in 
the control of locomotor activity: Local infusion of DA induced locomotion 
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(Costall et al. , 1991 ; but see also Cool , 1986) and infusion of the neurotoxin 
6-0HDA into the nucleus accumben reduced locomotion in amphetamine-
treated rats (Kelly et al. , 1975). The dorsal striatum i involved in the control of 
sniffing and oral stereotypies since local 6-0HDA lesions reduced stereotypie 
in amphetamine-treated rats (Kelly et al., 1975). AP-5 injected into the nucleu 
accumbens induced strong locomotor timulation (Bury, 1987). 
Local infusion of the NMDA-antagoni ts AP-5 (Schmidt, 1986a), SDZ 
EAA 494 or dizocilpine (Imperato, 1990a) into the dorsal triatum enhanced 
sniffing in rats and induced locomotion. Infusion of NMDA had oppo ite 
effects, it reduced sniffing and locomotion in rat (Schmidt and Bury, 1988). In 
rats, unil aterally lesioned with 6-0HDA, dizocilpine increa ed contralateral 
turning induced by L-DOPA or by a D I-agonist but reduced turning induced 
by a D2-agoni st (Morelli and DiChiara, 1990). 
Thus, given systemically or locally, into the striatum or nucleus accumbens 
NMDA-antagonists induce a DA-like pattern of behavioural stimulation. The 
non-NMDA antagon i ts gamma- D-glutamyl-amino-methyl- ulphonic ac id 
and glutamic-acid-diethyl-ester had not effects (Schmidt, 1986b). 
Other basal ganglia nuclei: According to the proposed function of the indirect 
pathway (striatum, GPe, STN, GPiISNr; ee above) thi s pathway is also 
involved in locomotion. DA deficiency-induced exc itation of STN-neuron 
associated with locomotor hypoactivity can be reversed by les ion of the STN 
(DeLong, 1990; Azi z et al. , 1991 ) or by blockade of NMDA and AMPA 
receptors in the STN or GPi/SNr (Klockgether and Turski , 1990; Klockgether 
et al. , 1991 ). 
Movement initiaTion and execution 
Inacti vation of central DA neurotransmission by DA receptor-antagoni sts or 
midbrain neurotoxin lesion produces - as already described - catalepsy in 
rats. Besides, systemic admini stration of neuroleptics induces motor impair-
ments in a variety of tasks, for instance a di sruption of ac ti ve avoidance 
responding (e.g. Fibiger et al. , 1975 ; Spirduso et aI. , 198 1), an impairement of 
reaction time performance (Amalric and Koob 1987) or di sturbances of 
operant responding in lever re lease task (Fowler et al. , 1984, 1986; 
Skjoldager and Fowler, 1988). These different behavioural impairments are 
thought to be predominantly due to the animals inability to initi ate motor 
behaviour, thus suggest ing a dopami nergic in vo lvement in the initi at ion of 
voluntary movements. 
In order to get further insight into the role of dopamine in the control of 
initiation and execution of motor behaviour we developed a novel imple 
reaction time task for rats. Thi s task demands rapid initiation of locomoti on in 
response to a stimulus in order to receive a food reward. Brie fl y. a modified 
runway was used which consisted of a start box and a run way terminating in a 
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goal box. A trained, gradually food deprived rat wa placed into the start box 
with the face to the closed guillotine door blocking the entrance to the runway. 
After a variable delay, the timulu signalled the simultaneous openjng of the 
front door. In response to the stimulus, a rat injtiated locomotion and moved 
through the runway to the goal box to get a food reward. The transition from 
stance to locomotion wa recorded by means of a photoelectronic witch 
ituated in front of the tart box and a force platform mounted below the start 
box. The following measures can be taken from each trial : reaction time 
(latency between stimulus presentation and movement initiation), movement 
time (latency between movement initiation and leaving of the tart box) and 
the initial acceleration (quantified by the rate of force development and peak 
force of the accelerative force) (Hauber, I 990b). 
Neuroleptic-induced akjnesia and bradykinesia 
Systemic administration of haloperidol (0.15 , 0.3 mg/kg, i.p.) induced specific 
impairments of movement initiation and execution in thi s paradigm: I) a 
del ayed initiation of locomotion (termed here as akinesia) as measured by an 
increa e of reaction time and II) a slowed movement execution (termed here as 
bradykine ia) as measured by an increase of movement time and a decrease of 
initial acceleration (Hauber and Schmidt, 1990; Schmidt et aI., 1991 ). 
The haloperidol-induced increase of reaction time corresponds well to the 
neuroleptic-induced prolongation of response latencies obtained in other rodent 
paradigms (Amalric and Koob, 1987 ; Spirduso et aI., 1981 ). These findings 
further support the concept of a DA involvement in the initiation of movement. 
The haloperidol-induced lowing of movement execution and decrease of the 
dynamic indice of a movement is also consistent with earlier observations of 
neuroleptic actions on movement time and force production (e.g. Fowler et aI. , 
1986). In addition, deficits of force production are found in patients with 
Parkinson's di sease (Stelmach and Worringham, 1988; Wierzbicka et aI., 1991 ). 
Thus, DA is not only a prerequisite for rapid initiation of a movement but 
also subserve the adequate regulation of force and time paramenters of a 
movement. 
The neuroleptic-induced pattern of impairment observed in the task de-
cri bed here are remini scent to akine ia and bradykinesia seen in parkinsonian 
patients. Thus the paradigm may be a useful model to investi gate potential 
Parkinson drugs . 
Reversal of neuroleptic-induced akinesia and bradykinesia 
We further examined whether different non-competitive (dizocilpine, 
amantadine, memantine) and competitive (CGP 37849) NMDA-antagonists as 
well a a DA-agoni st (bromocriptine) are able to reverse haloperidol-induced 
ak ine ia and bradykine ia in thi s paradi gm. 
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Single admi nistration 
Fir t we investigated the effect of the e compound on mo ement inItI atIOn 
and execution when given alone, re pectively. It wa found that dizoci lpine 
(0 .08 mg/kg i.p.), amantadine (44 mg/kg, i.p.), memantine (10 mg/kg, i.p.), 
CGP 37849 (4 mg/kg, i.p.) or bromocriptine ( 10 mg/kg, i.p.) eau ed no pro-
nounced alterations of reaction time performance (only amphetam ine (I mg/ 
kg, i.p. ) induced a significant decrease of reaction time). 
Regarding the effects on movement execution marked di fference were 
detected. Dizocilpine and - le s potently - amantadine induced a mild increa 
of movement performance (decrea e of movement time and/or increase of 
initial acceleration), memantine and - le potentl y - CGP 37849 produced a 
prominent decrea e (increase of movement time and/or decrease of initi al 
accelerati on) of movement performance. The decrea e of movement perfo rm -
ance induced by the latter two sub tances seem to be due to the ir mu c le 
re laxant properti es. Bromocriptine a lso produced a li ght decrease of mo e-
ment performance (Hauber and Schmidt, 1990; Schmidt et aI. , 199 1' Hauber, 
unpubli shed observati on ). The findings on movement execution are in line 
with the stimulatory effects on pontaneous motor act ivity hown fo r 
dizocilpine (C1 ineschmidt et aI. , 1982) and amantadine (Maj et aI. , 1974) and 
the CGP 37849-induced reduction of spontaneous locomotion (Kretschmer 
et aI. , 1992) . 
Coadmini trati on with haloperidol 
The increa e in reaction time (akine ia) induced by a single administrati on of 
haloperidol (0. 15 mg/kg, 0.3 mg/kg, i.p.) was antagonized by coadmini trati on 
of dizocilpine (0 .08 mg/kg, i.p.), CGP 37849 (4 mg/kg, i.p.) or bromocriptine 
(I 0 mg/kg, i.p. ). The anti-alU netic effects of amantadine (44 mg/kg, i.p.) or 
memantine ( 10 mg/kg, i.p.) were le s pronounced. These findings are 
consti stent with the anti -catalepti c ac ti vity of di zocilpine (Schmidt and Bubser, 
1989: Elliott et aI. , 1990; Mehta and Ticku . 1990), CGP 37849 (Kretschmer et 
aI. , 1992), bromocriptine (Colpaert, 1987: Boissier et al. 1980), amantadine 
(Maj et aI. , 1974) and memantine (Schmidt et al.. 199 1). 
In contrast, haloperido l-induced s lowing of movement exec ution 
(bradykine ia) was antagoni zed onl y by coadmini strati on of di zoc ilpine or -
less potentl y - by amantadine. Memantine. CGP 37849 or bromocriptine 
produced no anti -bradykineti c effects. (Hauber and Schmidt , 1990; Schmidt et 
aI. , 1991 ; Hauber, 1992) . The lack of anti-bradykinetic effects of memantine 
and CGP 37849 could be ex plained by the ir marked muscle re laxant properti e 
which can be already observed when given alone and - as in ca e of 
coadmini stration with haloperidol - the e properti e prevent a restorati on of 
impaired movement perfo rmance. The absent anti -bradyk inetic effect of 
bromocriptine is most probabl y due to the fact that stimulatory effect. of 
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bromocriptine on locomotor activity are only prominent in mice, and 
stereotypies, competing with locomotor behaviour, are predominant in rats. 
Thus, the use of bromocriptine as a reference substance in this test is of limited 
value. 
In conclusion, competitive and non-competitive NMDA antagonists have 
marked anti-akinetic effects. However, considerable differences exist in the 
anti-bradykinetic effects of these compounds. Provided that the paradigm used 
here represents a model of Parkinson's disease, these findings confirm that the 
u e of NMDA-antagonists may be a novel strategy for the treatment of thi s 
disea e. The differential anti-akinetic and anti-bradykinetic profiles of these 
NMDA antagonists may be an important criterion to assess their clinical 
potential. 
Local admini stration of drugs and neurotoxins 
Result from numerous studies support the hypothesis that nigrostriatal DA 
has an essential role in the initiation of motor acts. Depletion of DA in the 
striatum impaired reaction time performance of rats in operant tasks (AmaLric 
and Koob, 1987; Spirduso et aI., 1985) and in visual discrimination tasks (Carli 
et aI., 1985; Brown and Robbins, 1989, 1991). Local striatal infusion of 
haloperidol but not of carbachol also delayed movement initiation (Amalric 
and Koob, 1987). 
Since DA depletion in the nucleus accumbens did not impair reaction time 
performance (Amalric and Koob, 1987), the mesolimbic DA system seems not 
to be in volved in reaction time proces ing. On the other hand 6-0HDA lesions 
of the medial prefrontal cortex produced a prolongation of reaction time of rats 
(Hauber et aI., 1991 ). From these results one may conclude that not only 
nigrostriatal DA subserves rapid initiation of movements, but also cortical 
prefrontal DA contributes to intact movement initiation. 
According to the parallel loop model of basal ganglia functions, medial 
"cognitive" and lateral sen orimotor region of the frontal cortex innervate 
medial and lateral regions of the rodent striatum. An important implication of 
thi s concept i that di sruption at different points of the same loop should cause 
similar behavioural deficit . In fact, thi s has been confirmed in many studies 
(e.g. Divac and Oberg, 1979). For instance, we found that lesions of the 
prefrontal ' cortex or blockade of NMDA receptors by local infusion of AP-5 
into the corresponding medial stri atum induced similar learning impairments 
in a maze task (Hauber and Schmidt, 1989; Bubser and Schmidt, 1990; Bubser 
et aI., 1991 a). These results confirm the participation of the "cognitive" 
cortico-striatal loop in maze learning. Since lesions of the prefrontal cortex 
caused - as already described - an increase of reaction time we expected a 
similar impairment following lesions of the medial striatum. Indeed, it was 
found that quinolinic acid lesions in the medial striatum but not lateral triatum 
prolonged reaction time (Hauber et aI. , 1991 ). This result is in line with a 
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imilar finding fo llowing ibotenic ac id le ion in th med ial or lateral region of 
the triatum (Brown and Robbin , 1989) . 
Taken together, a le ion within the cogni tive loop at le el of the medi al 
striatum induced a delayed movement initiation. A di ruption of the DAergic 
modulation of thi loop at the level of the prefrontal cortex or the triatum 
produced similar deficit . Thus, the cognitive loop may proces info rmation 
related to movement initiation. This hypothe i i in accordance with r cent 
studies in primates and parkin onian patient (Montgomery and Buchholz, 
199 1; Montgomery et aI. , 199 1 a, b) leading to the conclu ion that the cognitive 
loop may be uniquely suited to assess the behavioural context nece ary fo r the 
decision when to move and the motor loop may be unique ly uited to decide 
how to move (Montgomery et aI. , 1991 a) . 
Biochemistry 
Methods jor analyzing dopaminergic junctions 
Until a decade ago, the biochemical analy i of drug effect on the function of 
DAergic ystems was mainl y re tri cted to the determination of DA, it precur-
sors and its metabolites in post-mortem brain tissue. By these mean only 
indirect estimates of DA functi on are gained (see Wood and Altar, 1988). The 
parameters measured include I) the rate of L-DOPA accumulation and the rate 
of di sappearance of DA after inhibition of tyrosine hydroxy lase or DOPA-
decarboxylase ( ee Lilj equi st et aI. , 199 1; Svensson et al.. 199 1). 11) the 
content of the extracellul arl y fo rmed DA metabolite 3-MT that i regarded a 
an index of DA re lease (Westerink, 1985 ; Wood and Altar, 1988; Hea l et a l.. 
1990), Ill ) the content of DOPAC, a metabo lite that is predominantl y fo rmed 
intraneuronall y after re-uptake of re leased DA has taken place, and IV) the 
metabolite/tran mitter rati os, e .g. DOPAC/DA and HVA/DA (Zigmond et aI. , 
1990). 
Recently, in-vi vo techniques like voltammetry and intracerebral mi cro-
dia ly. i have been developed, which enable neurosc ienti sts to determine in 
awake animal s the extracellul ar levels o f neurotransmitters and the ir 
metabolites in response to pharmacolog ical chall enge (for rev iews see 
DiChiara, 1990: Adams, 1990). 
Dopamine deficiency in man: Parkinson s' disease 
In Parkin son 's di sease DA neurons of the midbrain (substanti a ni gra and 
ventral tegmental area) projecting to the stri atum (caudate nucleus and 
putamen) and to cortical areas degenerate (see Birkmayer and Riederer. 1985: 
Je llinger, 1991 ). In additi on to mesencephali c DA ys tems. noradrenergic. 
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erotonergic and peptidergic transmitter systems are also affected by 
Parkinson' di sease, but to a lesser degree (Jellinger, 1991). 
Due to DA neurodegeneration, the po t-mortem tissue content of DA in the 
striatum decreases; concomittantly the HVAlDA ratio increases (Zigmond et 
aI. , 1990). Although surviving DA systems are able to compensate a certain 
amount of cell 10 s (see below), the amount of released DA finally becomes 
insufficient to maintain intact behavioural functions. Usually, clinical symp-
toms of Parkinson 's disease are observed when tissue DA content in the 
caudate nucleus and putamen is reduced by approximately 80% (see Zigmond 
et aI. , 1990). 
Pharmacologically- induced dopamine deficiency 
Several pharmacological tools have been developed in order to mimick the 
pattern of neurodegeneration in Parkinson's di sease in experimental animals. 
DAergic neurodegeneration can be produced by intracerebral injections of the 
catecholaminergic neurotoxin 6-0HDA (Breese and Traylor, 1971; Jonsson, 
1983), by ystemic injection of MPTP (Rose et aI., 1989), which in the brain is 
converted by monoamine oxidase type B to the toxic molecule MPf>+ (Sayre, 
1989), or by intracerebral injection of MPf>+ (Beresford et aI., 1988). Each 
neurotoxin causes a rather selective de truction of DA neurons, resulting in a 
decrea e of ti sue DA content (Breese and Traylor, 1971 ; SchuItz et aI., 1989), 
but other monoaminergic systems are also affected (Russ et aI., 1991 ; Santiago 
et aI. , 1991 ). Reduction of DA content are accompanied by a le pronounced 
decrease of DOPAC and thus by an increase of DOPACIDA ratio (Robinson 
and Whishaw, 1988; Rose et aI., 1989; Schultz et aI. , 1989; Zigmond et aI. , 
1989). Furtheron, the firing rate of DAergic neurons increases (Zigmond et aI. , 
1990). By the e compen ating mechanisms DA function - as assessed by 
behavioural and biochemical mea ure - i not compromised as long as the 
striatal ti ue depletion of DA doe not exceed about 80%; further increases of 
DA depletion produce behavioural deficits and lead to a gradual reduction of 
extracellular DA levels (Robinson et aI. , 1990). Depending on the extent of a 
lesion, either stimulated DA release alone (Robinson and Whi haw, 1988) or 
both timulated and basal re lease of DA are reduced (Castaneda et aI. , 1990; 
Bean and Roth , 1991 ). In rats, dramatic reductions of interstitial DA only 
occur with depletion of stri atal DA by more than 95 % (Castaneda et aI. , 1990). 
In contrast to neurotoxins that cause irreversible dysfunction of DAergic 
neuron , re erpine on ly de troys the pre ynaptic ves icles containing biogenic 
amines . Following admini tration of reserpine, brain DA content and the level 
of the extracellular DA metabolite 3-MT decline rapidl y, whereas the 
intracellular metabolites DOPAC and HVA increase (Westerink, 1985). 
Inhibition of DA ynthe i by blockade of the the rate-limiting enzyme -
tyrosine hydroxylase - with a-M PT, also reduces DA relea e in a reversible 
fa hi on (Shimizu et aI. , 1990: Abraini et aI. , 1991 ). 
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NMDA-antagonists and dopaminergic junctiolls 
Behavioural tudies indicate that pontaneou behaviour i differentially af-
fected by competitive and non-competitive NMDA-antagoni t ( ee abo e). In 
order to elucidate whether these effect are due to differential interaction with 
DA sy terns, we analyzed the effect that the non-competiti e NMDA-antago-
nists dizocilpine and memantine and the competiti ve NMDA-antagoni t CGP 
39551 exert on locomotor activ ity in an open fie ld and on DA ynthe i and 
metabolism in the basal ganglia ( triatum and nucleus accumbens). 
Both dizocilpine (0.33 mglkg) and memantine (20 mglkg) induced loco-
motor hyperactivity and increa ed DOPAC/DA in the nucleus acc umben , but 
not in the striatum, whereas CGP 39551 ( 10 and 20 mglkg) affected neither open 
field ac ti vity nor DA metaboli sm of the forebrain (Bub er et a I. , 199 1: 
Keseberg et aI. , 1991 ). Several other authors have al 0 reported a stimulati on of 
subcortical and cortical DA metaboli sm by the non-competitive NMDA-
antagonists PCP, ketamine and dizocilpine (Deutch et aI., 1987; Rao et aI., 
1990a, b; Tanii et aI. , 1990; lrifune et a I. , 1991 ; Liljequi t et aI. , 1991 ; Svensson 
et aI., 1991 ). The lack of effect of competiti ve NMDA-antagoni ts (AP-5 , 
AP-7 , CGS-19755, CPP and SDZ EAA 494) on ubcortical DA metabolism is 
also well established (Rao et aI. , I 990b, 199 1; Sven son et aI.. 199 1). 
The pattern of ac ti vation described above is in accordance with the differ-
enti al effects of competitive and non-competitive NMDA-antagon i t on the 
firing pattern of midbrain DA neurons (French and Ceci , 1990' French et a I. , 
1991 ) and on regional cerebral brain metaboli sm (Chapman et aI. , 1990' Clow 
et aI. , 1991 ; Tamminga et aI. , 1991 ). 
Let us now consider. how the DA-re leas ing effect of NMDA-antagoni sts 
may be mediated. For quantitative reasons it is unlike ly that NMDA-antago-
nists exert their DA-relea ing effects via presynaptic mec hani sm at DA 
terminal within the basal gangli a, since more than 90% of striatal NMDA 
receptor are located at postsynaptic sites (Greenamyre and Young, 1989, see 
below). However, there remain two ite - each within the ide loop from the 
stri atum to the substantia ni gra - where NMDA-antagonist may exert the ir 
effects on DA function : I) the DA cell groups of the midbrain and II ) the 
GABAergic efferents of the striatum and nucleus accumbens. 
E.g., it has been shown that blockade of NMDA receptor by dizocilpine 
increases firing rate of midbrain DA neurons (French and Ceci, 1990) and DA 
metabolism in DA terminal area (Rao et aI. , 1990a) . A second s ite of ac ti on 
seems to be located in the stri atum and nuc leus accumbens, si nce local 
infusion of NMDA-antagonists into these nuc le i increased DA re lease 
(lmperato et aI., 1990a, b). Thi s effect may be due to reduced exc itation of the 
striatonigral GABAergic feedback loop which resu lts in a decrease of GABA 
re lease in the substanti a ni gra. Since intrani gral GABA inhibits stri atal DA 
re lease (Re id et a I. , 1990), reduced GABAergic activity in the sub tanti a ni gra 
may in turn enhance stri atal DA re lease. [n thi s respec t it is interestin g to not e 
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that not only NMDA-antagonists, but also lesions of the prefrontal cortex 
which sends glutamatergic efferents to the striatum and the midbrain increase 
the firing rate of mesencephalic DA neurons (Ceci and French, 1989). 
In conclusion, the data presented here imply that non-competitive NMDA-
antagonists produce ome of their behavioural effects by a DA-dependent 
mechanism, since they are able to increase DA activity. However, the effects of 
non-competitive NMDA-antagonists can not solely be due to an interaction with 
DA systems, since they induce locomotion even in reserpinized mice (Carlsson 
and Carlsson, 1989) and in rats with lesion of the mesolimbic DA system, high 
doses of NPC 12626, a competitive NMDA-antagonist, induce locomotion 
(French et aI., 1991). Furtheron high do es of SDZ EAA 4949 also induce loco-
motion in intact animals without affecting DA activity (Svensson et aI., 1991). 
Glutamate-antagonists and Parkinson's disease 
It is proposed that DA-deficiency that induces catalepsy, reduces locomotion 
and sniffing and that impairs movement-initiation and execution represents an 
animal model for parkinsonian symptoms. Pharmacological reversal of these 
deficits by GLU-antagonists may give some indications for possible future 
therapy of the disease. 
The non-competitive NMDA-antagoni t dizocilpine was found to be 
maximally active in all the above tests but already in the rat, undesirable 
effects are obvious. These are ataxias, short-term memory deficits (Bischoff 
and Tiedtke, 1992) as well as stereotyped locomotion and sniffing instead of 
exploratory behaviour. 
Competitive NMDA-antagonists do not induce such pronounced ataxias. 
Amnesia is induced only by a much higher dose than necessary to relieve 
rigidity and there is no induction of stereotyped running (Bischoff and Tiedtke, 
1992; Kretschmer et aI., 1992). Allosteric manipUlation of the NMDA receptor 
by the glycine binding site may eventually be a promising strategy if it turns 
out that the isosteric NMDA-antagonists have too powerful side effects. 
Given systemically, blockers of AMPA receptors have locomotion inducing 
effects when coadministered with L-DOPA (Loschmann et aI., 1991 ; Klock-
gether et aI., 1991). 
Thu , the multiple sites for pharmacological intervention in the GLUergic 
system may provide the basis for the development of drugs with the desired 
specificity against parkinsonian symptoms. Further, while under L-DOPA medi-
cation DA receptor densities decrease this would be not the case with GLU-
antagonists. Additionally, in Parkinson 's disease the DAergic sy tern degener-
ates, the GLUergic does not: no changes in NMDA receptor affinity and density 
have been found in the striatum. Thus, striatal NMDA receptors remain intact 
which is required for potential therapeutic use ofNMDA-antagonists (Holemans 
et aI., 1991). 
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AP-5 
AP-7 
CGP 37849 
CGP 39551 
CGS-19755 
CPP 
CPPene 
DA 
DCS 
Dizocilpine (M K-80 I) 
L-DOPA 
DOPAC 
GABA 
GLU 
GPe 
GPi 
GYKl52466 
HVA 
a-MPT 
MPP+ 
MPTP 
3-MT 
NBQX 
NMDA 
NPC 12626 
6-0HDA 
SCH 23390 
SNc 
SNr 
SDZ EAA 494 (CPPene) 
STN 
THAL 
Abbreviations and drugs 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
2-ami no-5-phosphonova leric acid 
2-amino-7-phosphonoheptanoic acid 
(e)-2-amino-4-methyl-5-phosphono-3-pentanoic acid 
(e)-2-amino-4-methyl-5-pho phono-3-pentanoic acid elhylester 
cis-4-phosphonomethyl-2-piperidine-carboxy li c ac id 
3-(2-carboxypiperazin-4-yl)-propyl- l-phosphonic acid 
see SDZ EAA 494 
dopamine 
D-cycloserine 
(+ )-S-methyl-I 0, I l -dihydro-S H-dibenzla,dJ-cyclohepten-5, 10-
imine 
L-3,4,-dihydroxyphenylalanine 
dihydroxyphenylacetic acid 
gamma-aminobut yric acid 
L-glutamic acid 
globus pallidus ex ternal segment 
globus pallidu internal segment 
(4-amino-phenyl)-4-methyl-7 ,8-methylene-dioxy-S H-2.3-
benzodiazepine-HCI 
homovanillic acid 
a-methyl-p-ryrosine 
l-methyl-4-phenylpyridinium 
l -melhyl-4-phenyl- I,2.3.6-tetrahydropyridine 
3-methoxytyramine 
6-nilro-7 -su Ifamobe nzo(f)q uinoxal ine-2 ,3-dione 
-meth y I-d-aspartate 
2-amino-4.5-( 1,2-cyclohexyl)-7 -phosphonoheptanoic acid 
hydrate 
6-hydroxydopamine 
(RH + )-8-chloro-2.3.4.5-tetrahydro-3-methyl-5-phenyl-1 H-3-
benzazepin-7-ol 
substanti a nigra par compacta 
substantia ni gra pars reticulata 
(E)-4-(3-pho phonoprop-2-en y I)-pi perazi ne-2 -carbo x y I ic ac id 
subthalamic nucleus 
thalamus 
